Key clinical point: The use of high-dose-rate brachytherapy was associated with significantly higher quality-of-life scores over the first 36 months post-treatment compared to low-dose-brachytherapy.
Major finding: No significant differences in toxicity were noted between the high-dose and low-dose groups, and quality-of-life scores were significantly higher in the high-dose patients. PSA nadir was significantly higher with HDRB compared to LDRB (1.02 vs 0.25, P < 0.0001, and significantly more LDRB patients reached a PSA of less than 0.4 ng/mL (13 vs 2, P < 0.0001).
Study details: The data come from a phase 2 randomized pilot study in which 15 men with low-risk and favorable-intermediate-risk prostate cancer underwent Low-Dose-Rate Brachytherapy (LDRB) and 16 underwent High-Dose-Rate Brachytherapy (HDRB).
Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.
Source: Reynaud T et al. Brachytherapy. 2021 Jul 5. doi: 10.1016/j.brachy.2021.05.010.